Mahamaya Lifesciences Complete Financial Statements
In FY2025, Mahamaya Lifesciences (MAHALIFE) reported revenue ₹118 Cr, net profit ₹5 Cr and EPS ₹3.04, with a net profit margin of 4.2% and ROE of 4.1%. Full financial statements from FY2022 to FY2026 (5 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Mahamaya Lifesciences screener.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
MAHALIFE Revenue, Net Profit & EBITDA — Year-on-Year Growth
MAHALIFE YoY (Dec 2024 vs Mar 2025). Examine MAHALIFE Q4 results for recent quarterly revenue, profit and EPS trends.
MAHALIFE Income Statement — Revenue, EBITDA & Net Profit
Mahamaya Lifesciences revenue ₹118 Cr, EBITDA ₹10 Cr, net profit ₹5 Cr, EPS ₹3.04 (2025) — net profit margin 4.2%. Analyse MAHALIFE FII DII holdings to track promoter, FII and institutional holdings.
| Particulars | Mar 2025 | Dec 2024 |
|---|---|---|
| Revenue | 118 | 0 |
| Expenses | 109 | 0 |
| EBITDA | 10 | 0 |
| Operating Profit Margin % | 8.00% | 0.00% |
| Depreciation | 1 | 0 |
| Interest | 3 | 0 |
| Profit Before Tax | 7 | 0 |
| Tax | 2 | 0 |
| Net Profit | 5 | 0 |
| Earnings Per Share (₹) | 3.04 | 0.00 |
MAHALIFE Balance Sheet — Assets, Liabilities & Shareholders' Equity
MAHALIFE total assets ₹310 Cr, total equity ₹122 Cr, total liabilities ₹ Cr (2026) — ROE 4.1%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| ASSETS | |||||
| Total Assets | 310 | 188 | 112 | 78 | 56 |
| Current Assets | 267 | 157 | 87 | 54 | 33 |
| Fixed Assets | 43 | 27 | 22 | 21 | 20 |
| Capital Work in Progress | 6 | 4 | 3 | 2 | 2 |
| Investments | 141 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 157 | 88 | 54 | 34 |
| LIABILITIES | |||||
| Total Liabilities | |||||
| Current Liabilities | 5 | 7 | 9 | 11 | 10 |
| Non-Current Liabilities | |||||
| SHAREHOLDERS' EQUITY | |||||
| Total Equity | 122 | 49 | 25 | 19 | 16 |
| Share Capital | 23 | 18 | 1 | 1 | 1 |
| Reserves & Surplus | 99 | 32 | 23 | 18 | 15 |
MAHALIFE Cash Flow Statement — Operating, Investing & Financing
Mahamaya Lifesciences operating cash flow ₹1 Cr, investing ₹-8 Cr, financing ₹9 Cr, net cash flow ₹1 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 |
|---|---|---|---|---|
| Operating Activities | 1 | -23 | 1 | 2 |
| Investing Activities | -8 | -2 | -3 | -3 |
| Financing Activities | 9 | 24 | 2 | 1 |
| Net Cash Flow | 1 | 0 | 1 | 0 |